Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/51422
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12642]
Metadatos
Mostrar el registro completo del ítem
TARGETING MICROBIOME: AN ALTERNATIVE STRATEGY FOR FIGHTING SARS-COV-2 INFECTION
Disbiose
Eixo intestino-pulmão
Probióticos
Tempestade Sistêmica de Citocinas
Microbioma
SARS-CoV-2
COVID-19
Gut-lung axis
Probiotics
Systemic cytokine storm
SARS-CoV-2
Targeting Microbiome
Autor
Afiliación
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas, Laboratório de Genética Celular e Molecular. Belo Horizonte, MG, Brasil.
Unit of Clinical Laboratory Science, University of Biomedical Campus. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy / Migrant and Global Health Research Organization (Mi-HeRo), Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas, Laboratório de Genética Celular e Molecular. Belo Horizonte, MG, Brasil.
Unit of Clinical Laboratory Science, University of Biomedical Campus. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy / Migrant and Global Health Research Organization (Mi-HeRo), Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Resumen en ingles
Respiratory and gastrointestinal symptoms are the predominant
clinical manifestations of the coronavirus disease 2019
(COVID-19). Infecting intestinal epithelial cells, the severe
acute respiratory syndrome coronavirus-2 may impact on
host’s microbiota and gut inflammation. It is well established
that an imbalanced intestinal microbiome can affect pulmonary
function, modulating the host immune response (“gutlung
axis”). While effective vaccines and targeted drugs are
being tested, alternative pathophysiology-based options to
prevent and treat COVID-19 infection must be considered on
top of the limited evidence-based therapy currently available.
Addressing intestinal dysbiosis with a probiotic supplement
may, therefore, be a sensible option to be evaluated,
in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration
in preventing and treating COVID-19 pneumonia.
Palabras clave en portugues
COVID-19Disbiose
Eixo intestino-pulmão
Probióticos
Tempestade Sistêmica de Citocinas
Microbioma
SARS-CoV-2
Palabras clave en ingles
DysbiosisCOVID-19
Gut-lung axis
Probiotics
Systemic cytokine storm
SARS-CoV-2
Targeting Microbiome
Compartir